RA'ANANA, Israel, Dec. 27,
2024 /PRNewswire/ -- Inspira Technologies Oxy
B.H.N. Ltd. (NASDAQ: IINN), (NASDAQ: IINNW), ("Inspira
Technologies," "Inspira" or the "Company"), a
groundbreaking respiratory support technology company, a pioneer in
life-support technology, today announced the pricing of a private
placement offering consisting of the issuance and sale of 4,608,715
ordinary shares, no par value per share (or pre-funded warrants in
lieu thereof) and ordinary warrants to purchase up to 4,608,715
ordinary shares, at a combined purchase price of $0.70. The ordinary warrants have a term of
eighteen months and have an exercise price of $1.10 per share.
The Company intends to use the net proceeds from the offering
for working capital and general corporate purposes. The closing of
the private placement is expected to occur on or about December 30, 2024, subject to the satisfaction of
certain customary closing conditions.
Dawson James Securities is acting as the exclusive placement
agent for the private placement.
The securities described above were offered pursuant to an
exemption from the registration requirements under Section 4(a)(2)
of the Securities Act of 1933, as amended (the "Securities Act"),
and Rule 506(b) of Regulation D promulgated thereunder. The
securities have not been registered under the Securities Act or
applicable state securities laws. Accordingly, the securities may
not be offered or sold in the United
States except pursuant to an effective registration
statement or an applicable exemption from the registration
requirements of the Securities Act and such applicable state
securities laws.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Inspira™ Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company
in the life support and respiratory treatment arena. The Company
has developed a breakthrough Augmented Respiration Technology
(INSPIRA™ ART), a groundbreaking device poised to
revolutionize the $19 billion
mechanical ventilation market. With 20 million intensive care unit
patients with acute respiratory failure each year, many of whom
rely on mechanical ventilators, the INSPIRA ART offers a potential
alternative by elevating and stabilizing decreasing oxygen
saturation levels in minutes without a ventilators, with patient
being awake during treatment. The INSPIRA ART is being equipped
with the HYLA™ blood sensor technology, a real-time continuous
blood monitoring technology, aiming to alert physicians of changes
in a patient's condition without the need for intermittent actual
blood samples, and potentially supporting physicians in making
informed decisions.
The Company's INSPIRA™ ART100 system has obtained FDA
510(k) clearance for use in Cardiopulmonary Bypass procedures,
along with the Israeli AMAR certification for both Extra-Corporeal
Membrane Oxygenation and Cardiopulmonary Bypass procedures.
The Company's other products and technologies, including the
INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the
INSPIRA™ Cardi-ART portable modular device, VORTX orbiting Oxygen
Delivery System and HYLA™ blood sensor, are currently being
designed and developed, and have not yet been tested or used in
humans and have not been approved by any regulatory entity.
For more information, please visit our corporate website:
https://inspira-technologies.com.
Forward-Looking Statements
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the expected use of
proceeds and the expected closing of the private placement. These
forward-looking statements and their implications are based solely
on the current expectations of the Company's management and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Except as otherwise required by law,
the Company undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's annual report on Form 20-F for the
fiscal year ended December 31, 2023
filed with the U.S. Securities and Exchange Commission (the "SEC"),
which is available on the SEC's website, www.sec.gov.
Contact:
For more information, contact:
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
Logo -
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-announces-pricing-of-3-2m-private-placement-by-new-and-existing-investors-of-the-company-302339638.html
SOURCE Inspira Technologies
